Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

Published:2009-09 Issue:13 Volume:45 Page:2316-2323
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Thomas Fabienne,Rochaix Philippe,White-Koning Melanie,Hennebelle Isabelle,Sarini Jérôme,Benlyazid Adil,Malard Laurence,Lefebvre Jean-Louis,Chatelut Etienne,Delord Jean Pierre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma;Thomas;Clin Cancer Res,2007

2. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer;Lu;Clin Pharmacol Ther,2006

5. Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes;Li;Clin Cancer Res,2007

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment;Beni-Suef University Journal of Basic and Applied Sciences;2024-07-26

2. Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy;Molecules;2023-05-08

3. HER Receptor, Current, and Emerging Therapeutic Targets;Handbook of Cancer and Immunology;2023

4. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer;Pharmaceutics;2022-09-01

5. Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status;Frontiers in Oncology;2022-08-30